Get the Stockscreener App
0.759
3.97%
0.029
After Hours:
.73
-0.029
-3.82%
Acurx Pharmaceuticals Inc stock is traded at $0.759, with a volume of 135.61K.
It is up +3.97% in the last 24 hours and down -11.02% over the past month.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
See More
Previous Close:
$0.73
Open:
$0.74
24h Volume:
135.61K
Relative Volume:
0.53
Market Cap:
$14.04M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-0.66
EPS:
-1.15
Net Cash Flow:
$-9.80M
1W Performance:
-8.34%
1M Performance:
-11.02%
6M Performance:
-65.66%
1Y Performance:
-78.62%
1-Day Range:
$0.71
$0.7599
1-Week Range:
$0.704
$0.8716
52-Week Range:
$0.68
$3.77
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
0.759 | 14.04M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
Geode Capital Management LLC Increases Stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Acurx Pharmaceuticals Inc (ACXP) - SETE News
HC Wainwright Reaffirms Buy Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World
Acurx Pharmaceuticals (NASDAQ: ACXP) Announces $2.5 Million Registered Direct Offering - Defense World
Acurx pharmaceuticals director Carl Sailer acquires shares worth $25,000 - Investing.com
Acurx pharmaceuticals director Joseph Scodari acquires $25,000 in stock - Investing.com
Acurx pharmaceuticals director Carl Sailer acquires shares worth $25,000 By Investing.com - Investing.com UK
Acurx Pharmaceuticals director buys $9,999 in common stock - Investing.com
Acurx Pharmaceuticals director Robert DeLucca buys $49,999 in stock By Investing.com - Investing.com South Africa
ACXP stock touches 52-week low at $0.72 amid market challenges - Investing.com Canada
Acurx Pharmaceuticals Secures $2.5M Financing Through Direct Offering and Warrant Placement - StockTitan
Form 424B5 Acurx Pharmaceuticals, - StreetInsider.com
SEC Form 424B5 filed by Acurx Pharmaceuticals Inc. - Quantisnow
Acurx to sell 2.46M shares at $1.015 in registered direct offering - MSN
Acurx Pharmaceuticals announces $2.5 million registered direct offering - MSN
Acurx gains EMA support for ibezapolstat Phase 3 trial By Investing.com - Investing.com Nigeria
Acurx gains EMA support for ibezapolstat Phase 3 trial - Investing.com
Acurx's Ibezapolstat Secures EMA Backing for Phase 3 C. Difficile Treatment Program - StockTitan
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year? - Yahoo Finance
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Increase in Short Interest - Defense World
Acurx Pharmaceuticals to Present Latest Antibiotic Developments at 2025 Microcap Conference - StockTitan
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025January 30, 2025 - Eagle-Tribune
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 - Kilgore News Herald
Acurx prepares for Phase 3 trials in C. difficile treatment By Investing.com - Investing.com Canada
Acurx prepares for Phase 3 trials in C. difficile treatment - Investing.com India
Acurx's Breakthrough CDI Antibiotic Advances Toward Global Phase 3 Trial Following FDA Green Light - StockTitan
ACXP stock touches 52-week low at $0.79 amid market challenges - Investing.com UK
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now - MSN
ACXP stock touches 52-week low at $1.01 amid market challenges - Investing.com Canada
Novavax and Assembly lead infectious disease gainers in 2024 - BioWorld Online
MicroStrategy Now Has Copycats Buying Bitcoin as Prices Near $100,000 - Barron's
Nasdaq-Listed Acurx Invests $1M in Bitcoin—What’s Behind the Move? - Watcher Guru
Acurx Pharmaceuticals Allocates $1 Million to Bitcoin as Reserve Asset, Shares Slide 26% - Binance
Acurx Pharmaceuticals Shares Slide 17% After Disclosing Bitcoin Investment - MarketWatch
Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook - MSN
ACXP stock touches 52-week low at $1.5 amid market challenges - Investing.com UK
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset - Il Giornale d'Italia
Acurx Pharmaceuticals adopts Bitcoin as a reserve asset - TU News
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset | DigitalMore.co - Digital More
Acurx Pharmaceuticals allocates $1M for Bitcoin reserve - Investing.com
Acurx Pharmaceuticals allocates $1M for Bitcoin reserve By Investing.com - Investing.com UK
ACXPAcurx Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Acurx Pharma Advances CDI Drug to Phase 3 Trials After Promising Clinical Data | ACXP Stock News - StockTitan
HC Wainwright Has Bullish Estimate for ACXP FY2024 Earnings - Defense World
Acurx Pharmaceuticals Reports Q3 2024 Financial Results and Business Update - Defense World
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Decline in Short Interest - Defense World
Acurx Pharmaceuticals’ (ACXP) Buy Rating Reiterated at HC Wainwright - Defense World
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):